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We discuss inference for longitudinal clinical trials subject to possibly informative dropout.
A selection of available methods is reviewed for the simple case of trials with two timepoints.
Using data from two such clinical trials, each with two treatments, we demonstrate that
different analysis methods can at times lead to quite different conclusions from the same
data. We investigate properties of complete-case estimators for the type of trials considered,
with emphasis on interpretation and meaning of parameters. We contrast longitudinal and
crossover designs and argue that for crossover studies there are often good reasons to prefer a
complete case analysis. More generally, we suggest that there is merit in an approach in which
no untestable assumptions are made. Such an approach would combine a dropout analysis,
an analysis of complete-case data only, and a careful statement of justified conclusions.
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1 Introduction
Over the last 20 or so years an impressive array of methods has been developed for missing
data problems in general and dealing with dropout in longitudinal trials in particular1–8.
Many of these contributions have been deeply thought-provoking and technically highly
accomplished. Nevertheless, whatever the technical virtuosity of these methods they cannot
make missing data appear. As has been widely recognised9, almost all of the methods
rely for their validity either on questionable assumptions about the missingness process, or
by making untestable assumptions with regard to unobserved outcomes. Consequently it
is now generally accepted, and formally recommended8, that an analysis of data subject to
missingness should include a careful assessment of sensitivity of conclusions to the underlying
assumptions.
In this paper we take a different view. We use two simple two-timepoint randomized trials
to illustrate some of the techniques now available for dealing with dropout from longitudinal
data, and as a basis for discussion of a number of foundational issues. We will argue that
dropout from a longitudinal clinical trial should not be treated as a special case of a generic
missing data problem, but as a different case, since the special role of time should be taken
into account. We will suggest that a structured analysis that does not rely on untestable
assumptions can in certain circumstances be not just a practicable but an appropriate strat-
egy. In particular, for the situations in which a crossover trial is applicable we will propose
that a complete case analysis provides a proper basis for inference.
When dealing with generic missing data it is customary to begin by introducing notation
(Yobs, Ymiss) for observed and missing components of a response vector Y . Alongside this we
have a vector R of response indicators, with elements taking the value one if the correspond-
ing element of Y is observed, zero otherwise. The familiar Rubin classification of missingness
mechanisms is Missing Completely at Random (MCAR) if f(R|Yobs, Ymiss) = f(R), Missing
at Random (MAR) if f(R|Yobs, Ymiss) = f(R|Yobs) and otherwise Missing Not at Random
(MNAR). It is recognised that an appropriate analysis based only on Yobs can provide un-
biased parameter estimates if the missingness is assumed to be MCAR or MAR. However,
the validity of these assumptions cannot be detected without imposing additional untestable
structure, such as embedding a MAR model within a broader MNAR one, which cannot be
unique9.
Not all writers have fully accepted the Rubin missing data taxonomy or its generic application
to longitudinal data, for example10–12. Diggle et al11 assert that the notation (Yobs, Ymiss) is
too simplistic when missingness is caused by dropout in a longitudinal study. The argument
is that the notation Ymiss suggests that the underlying unobserved response is the same
whether or not it is observed. This is appropriate when the process that generates the
missingness pattern is exogenous to the process that generates the responses. Data may still
be MNAR, for example if an experimenter simply chooses not to record very low values, but
the extant value attached to the experimental unit does not in itself change depending on
whether or not it is observed. However, dropout in a longitudinal trial often corresponds
to an event in a subject’s life, such as withdrawing from treatment. Meinert13 makes the
important point that such treatment dropouts must be distinguished from analysis dropouts,
those who simply cease to be observed. Clearly what happens after dropout could be very
different from what might have happened in the absence of dropout. In other words if Ymiss
was not missing it could be something completely different. Considering dropout caused by
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death makes this point rather dramatically14.
Building from Diggle et al. we suggest that the use of counterfactual notation should be
taken up more widely. We can think of potential outcomes Yt(0) and Yt(1) that correspond,
respectively, to the response when external intervention is not, or is, employed to prevent
dropout. As Didelez15 argues in her discussion of Diggle et al., such counterfactuals can
be sensibly defined and modelled provided the hypothetical intervention is made explicit; it
makes little sense to talk about a response Yt ‘in the absence of dropout’ without specifying
how this absence is to be achieved. Note that we are indexing by dropout (prevention) and
not conditioning on it, a distinction also made in Rubin’s causal model16. Such notation
helps make explicit the implicit assumption in most previous work that the properties of
Yt(1) are usually the targets for inference. Aalen and Gunnes
12 discuss the complexities of
attempting to separate a longitudinal response from the process that may cause it to be
missing, and describe why different inferential objectives may be appropriate in different
circumstances. Buyse17 takes a holistic view, and invites subject-matter experts to form a
hierarchy of contrasts that may include both longitudinal responses or survival outcomes, in
order to compare individuals undergoing different treatment regimes.
In this work we consider targets for inference for simple two-period clinical trials. Our
notation, assumptions and a short review of a selection of available methods are given in
Section 2. In Section 3 we present analyses of two such trials, each designed to compare
two treatments and in each of which a number of subjects dropped out before the second
measurement was collected. We show that a wide range of treatment effect estimates can
be obtained, depending on the method and assumptions adopted. Section 4 includes some
technical work on the properties of complete-case estimators for two-treatment two-period
designs. In Section 5 we argue that a transparent approach to an analysis of this type of
data requires a combination of a dropout analysis, a complete case analysis, and a careful
statement of conclusions that takes full account of the context of the analysis.
2 Notation, assumptions and methods
2.1 Methods
Suppose there are n subjects in a study and two observation or treatment periods. Subjects
provide a measurement at time 1, denoted Yi1 for subject i, but some subjects drop out before
measurement time 2. Let Ri = 1 indicate continuation to time 2 and Ri = 0 otherwise.
The possibly counterfactual second response, assuming hypothetically that dropout may be
prevented, is Yi2(1). For simplicity we will denote this by Yi2 but throughout we bear in
mind that our models and assumptions are predicated upon a possible counterfactual. Let
Yi = (Yi1, Yi2)
T and assume E[Yi] = Xiβ where β is a p−dimensional parameter vector and
Xi is a 2× p design matrix associated with subject i.
A raft of techniques is available for estimation, some of which are summarised here. We do
not attempt a full review and our list is certainly incomplete, with pattern mixture modelling,
multiple imputation18 and Bayesian methods notable omissions5. We focus in the main on
methods where the estimating equations can be written down in fairly simple form.
Complete Case, CC
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Estimation is restricted to subjects who provided both measurements and there is no esti-
mation or use of dropout probabilities. A variety of approaches are possible but a random
intercept model with Gaussian errors is common. If the marginal var(Yi) = Σ is known, the
maximum likelihood estimator βˆ solves the score equation
n∑
i=1
Ri
{
XTi Σ
−1(Yi −Xiβ)
}
= 0. (1)
In practice Σ would be unknown and simultaneous estimation of Σ and β is required.
Last Observation Carried Forward, LOCF
A procedure that has been common in practice, though much criticised3,8, is to carry forward
the last observed value and then pretend the data are complete. Let Y Ri = (Yi1, Yi2) if Ri = 1
and Y Ri = (Yi1, Yi1) if Ri = 0. Then the LOCF score corresponding to (1) is
n∑
i=1
{
XTi Σ
−1(Y Ri −Xiβ)
}
= 0, (2)
with the same comments on variance estimation.
Linear Mixed Effect, LME
Maximum likelihood estimation using only observed data yields consistent estimators under
MAR, without use of dropout probabilities4. Assuming a Gaussian random intercept model,
the score equation of current interest is
n∑
i=1
[
Ri
{
XTi Σ
−1(Yi −Xiβ)
}
+
(1−Ri)
σ21
{
xi1(Yi1 − xTi1β)
}]
= 0, (3)
where xTi1 is the first row of Xi and σ
2
1 = var(Yi1).
Diggle Kenward, DK
Diggle and Kenward19 take a fully parametric approach, combining assumptions of multi-
variate Gaussian response and logistic dropout probabilities. For the remainder of this paper
we will assume
Pr(Ri = 1|Yi1, Yi2) = pi(θ, θ2) = expit(θ0 + θ1Yi1 + θ2Yi2), (4)
where we use expit(u) to denote exp(u)/(1+exp(u)) and θ = (θ0, θ1). Taking θ2 = 0 gives
MAR dropout and θ1 = θ2 = 0 gives MCAR.
Diggle and Kenward19 propose likelihood inference based on a selection factorisation20. In
our terms the likelihood is
L =
n∏
i=1
{P (Ri = 1|Yi1, Yi2)f(Yi1, Yi2)}Ri {P (Ri = 0|Yi1)f(Yi1)}(1−Ri) . (5)
The contribution P (Ri = 0|Yi1) is obtained from the logistic model P (Ri = 0|Yi1, Yi2) by
integrating out Y2i with respect to its Gaussian conditional distribution given Yi1. Diggle
4
and Kenward suggest a probit approximation to logistic in order to obtain a closed form for
P (Ri = 0|Yi1). The same approximation will prove very useful to us in Section 4.
Linear Increments, LI
Diggle, Farewell and Henderson11 model the increments between observations at consecutive
measurement times, taking a martingale approach which has links with methods for event
history analysis. There are no distributional assumptions for either response or dropout,
other than linear models for the mean increments in responses and a martingale assumption
for within-subject random effects.
Their method is chiefly designed for processes in which the parameter β in the linear predictor
for the mean is assumed to vary with time. It can be extended in several ways21, and can
be adapted to give estimates of effects that are assumed to be time-constant, in our case
as follows. Let Di = Yi1 − Yi2 and di = xi1 − xi2; elements of the latter will be zero where
covariates are constant between measurement times. Recall that E[Yi1] = x
T
i1β and note that
E[Di] = d
T
i β. Ordinary least squares can be used to estimate β, leading to the estimating
equation
n∑
i=1
{
xi1(Yi1 − xTi1β) +Ridi(Di − dTi β)
}
= 0. (6)
Inverse probability weighted estimating equations with MAR assumption, IPMAR
In a series of papers22–24, Robins and colleagues proposed inverse probability of observation
weighted estimating equations. Again, no distributional assumptions are made about Yi,
other than a linear model for the mean, but a parametric model for dropout probability is
required. Although the authors discuss a variety of efficient estimating procedures, for our
purposes it is sufficient to concentrate on the simplest version of the proposals. In this case
θ2 in (4) is assumed known and the other dropout parameters θ = (θ0, θ1) are estimated
using the estimating equations
n∑
i=1
{
1− Ri
pi(θ, θ2)
}
pi(θ)
(
1
Yi1
)
= 0, (7)
where pi(θ) = expit(θ0 + θ1Yi1). The parameter of interest β is then obtained by solving the
weighted estimating equation
n∑
i=1
Ri
pi(θ, θ2)
{
XTi Σ
−1(Yi −Xiβ)
}
= 0. (8)
In the sequel we will refer to the combination of (7) and (8) under the MAR assertion that
θ2 = 0 as IPMAR.
Inverse probability weighted estimating equations with zero interaction procedure, IPZI, IPZI+
and IPZI-
There are no methods for estimating θ2 in (4) without further strong assumptions. Instead,
in order to apply (8) in the MNAR case it is usually recommended24–26 that an expert from
the application area be asked to specify either θ2 itself or a realistic range within which it
could feasibly lie. In the latter case the advice is usually to vary θ2 across the range and
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inspect the consequences for estimation of β, or perhaps to elicit a prior distribution for θ2
or a related quantity and derive an appropriate posterior summary27,28. Application experts
with the required abilities are likely to be in high demand, so there is merit in exploring
whether, in specific applications, more oblique approaches to sensitivity analysis might pay
dividends.
Ho and colleagues29 propose one such alternative, in which one untestable assumption is
traded for another. For crossover trials they propose that the value of θ2 that minimises the
estimated treatment by period interaction is sought. The resulting value, say θ20, is then
taken as the presumed value of θ2 in an analysis based on (7) and (8) which now excludes
by construction the possibility of interaction. Bootstrap methods can be used to estimate
the uncertainty attached to θ20.
Ho et al’s suggestion was aimed at crossover trials, where washout periods are specifically
included in carefully designed trials precisely to limit the possibility of interaction. It can be
applied more generally however, if we are prepared to make a zero interaction assumption.
In many cases it may be more straightforward to discuss such an assertion with subject-
specialist collaborators than to discuss possible values of the more abstract θ2.
We will refer to the use of the inverse probability weighted estimating equations (7) and
(8) with θ2 = θ20 specified to give zero estimated interaction as IPZI. To get some idea of
sensitivity we also propose that the parameters be estimated at θ2 = θ20+2SE(θ20) (IPZI+)
and at θ2 = θ20 − 2SE(θ20) (IPZI-).
2.2 Testable assumptions and the role of time
Most of the foregoing approaches are based on variants of selection models, in that they are
rooted in the distributions f(Y1, Y2) and f(R|Y1, Y2). Pattern mixture alternatives4,30 would
be based on the marginal f(R) and a mixture over R of and f(Y1, Y2|R), noting that while
f(Y1|R = 0) is identifiable, f(Y2 | Y1, R = 0) is not.
In Section 1 we stated that dropout in longitudinal trials should be treated as a different
type of missing data problem, rather than as a special case of a more generic approach. Both
pattern mixture and selection model classes are applicable to generic missing data problems
and neither is explicitly based on the fundamental feature of longitudinal studies: events
happen and conditions change as time proceeds inexorably. In this section we consider how
best to recognise temporal development, and, pre-empting later detailed discussion, suggest
that there can be situations where avoiding untestable assumptions can lead to clearer and
potentially more pertinent understanding of a longitudinal study.
Our suggestion is to employ only those features of pattern mixture and selection models
that do not require untestable assumptions, and in neither case to combine them. An
unavoidable feature of this approach is added complexity. Crucially, this complexity lies not
in mathematical subtleties, but in the required depth when reporting study findings.
Pattern mixture models offer several advantages in a longitudinal dropout context. Most
importantly, definitions of random variables are entirely unambiguous, for longitudinal re-
sponses are only modelled conditional on their existence, obviating the need for subtle
counterfactual descriptions11. The mixing is done over a clearly identified distribution —
the marginal distribution of the dropout indicator R — and familiar tools for longitudi-
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nal data analysis may be used to model the conditional distributions f(Y1|R = 0) and
f(Y1, Y2 | R = 1). However, making the latter distribution the subject of a model has
the disadvantage that it has no mechanistic interpretation. Because the observation of Y1
necessarily precedes the realisation of R, the model can provide no insight into the causal
mechanisms that may underlie the data. The reverse is true, too: any substantive insights
into the causal mechanisms linking previous responses to subsequent dropout cannot easily
be incorporated into pattern mixture models. Aalen and colleagues31,32 have written about
the need for greater recognition of the special role of time, and the ability to reason causally,
in the analysis of longitudinal data.
Selection models4 do admit causal (or mechanistic) thinking, by modelling the probability
of dropout conditional on previous observed responses, f(R = 0 | Y1). The corresponding
disadvantage comes when attempting to combine these dropout probabilities into a full, joint
likelihood: we then require marginal joint distributions of potentially unobserved random
variables (e.g. f(Y1, Y2)) with the accompanying ambiguities of definition.
We can follow a middle path by avoiding the mixing aspect and not attempting to specify a
full joint likelihood. Consequently, we are able to restrict ourselves to models requiring no
untestable assumptions. Moreover, the features of the analysis strategy we suggest have a
natural temporal progression, allowing causal thinking at each stage. We propose
1. Baseline analysis: model f(Y1). The first observation is observed for all subjects,
and yields the first opportunity to consider covariate effects on the longitudinal re-
sponse.
2. Dropout analysis: model f(R = 0 | Y1). The observation of Y1 occurs strictly
before R is realised, and is therefore admissible (since it previsible) as a covariate in a
(discrete-time) event history analysis. Such a model might tell us, for instance, that
extreme responders at time 1 were more likely to drop out of the longitudinal study.
3. Complete case analysis: model f(Y2 | R = 1, Y1). For those who continue to time
2, we can quite legitimately (and without untestable assumptions) describe how their
responses relate to their prior observation. Alternatively but essentially equivalently,
we might choose to model the changes f(Y2 − Y1 | R = 1, Y1).
The first two points are uncontroversial. In subsequent sections we shall consider in greater
detail the third component, including our claim that scientific understanding may in some
instances be no less complete when considering only complete cases at the second timepoint.
Our temporal sequence is reminiscent of the careful likelihood construction of Tsiatis and
Davidian33. By deliberately avoiding combining these components, we do not specify a joint
likelihood for R, Y1 and Y2. More than this, we cannot uniquely specify such a likelihood
without further structures or identifying assumptions. Our feeling is that this is a strength,
not a weakness.
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3 Illustrations
We consider data from two clinical trials, each with two treatments and two measurement
times.
3.1 A longitudinal trial with dropout
We first consider results on 422 subjects in an AA/BB longitudinal trial. The data are real
but not public. The trial was randomized and observations were taken pre-randomization
and at two times post-randomization: in this paper we consider only the post-randomization
observations. For confidentiality reasons we have scaled all observed responses by the mean
and standard deviation of the responses at time 1 and we will refer simply to treatment and
response without describing what they are.
There are no covariates other than treatment type and time. Without treatment by time
interaction the parameter vector is β = (µ, pi, τ), where µ is a general mean, pi measures the
effect of time and τ measures the treatment effect. The design matrices Xi are all either
(
1 1 1
1 −1 1
)
or
(
1 1 −1
1 −1 −1
)
depending on whether the subject is given treatment A or B respectively. Interest is osten-
sibly in τ .
All 422 subjects provided a response at time 1. Of 212 subjects receiving Treatment A, only
126 provided a response at time 2 and the other 86 dropped out. We have no information
on reason for dropout. Of 210 subjects receiving Treatment B, 193 continued to time 2 and
the other 17 did not.
Treatment effect estimates using the techniques described in Section 2 are shown in Figure
1 together with nominal 95% confidence limits. The estimates correspond to the methods
summarised in Section 2. The strongest treatment effect is evident under LOCF, with
complete case (CC) providing the least evidence of a difference between treatments. The four
inverse probability weighted methods are rather similar, and in most cases these techniques
have higher standard errors.
It is interesting to explore these data a little further. Figure 2 show a variety of mean
responses, alongside each of which is given the number of observations used in the calculation.
Standard deviations are not given but all are relatively small. Panel (a) of the figure is
essentially that used in the original trial report to summarise the data. It uses LOCF to
interpolate missing values at time 2, so that means are formed from the same number of
observations at each time point. Evidently there is a large treatment effect. Panel (b) shows
the means of only the observed data. Now the treatment effect seems to disappear at time
2. Its presence at time 1 is not surprising because subjects had already been on treatment
for some time before this response was collected, it was not a baseline score. Panel (c) is the
most informative presentation of the data: it separates the subjects at time 1 into those who
subsequently drop out and those who continue to time 2. Subjects who drop out tend to
have lower scores at time 1. Amongst the complete cases there is no evidence of a treatment
effect.
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Figure 1: Longitudinal trial: selection of estimated treatment effects and nominal 95%
confidence intervals
3.2 A crossover trial with dropout
Our second example is on data from an AB/BA crossover trial. The trial is reported in34
and is used to illustrate the Zero Interaction proposal29. The treatments are analgesics:
dihydrocodeine (A) and nabilone (B) and the response was a visual analogue score for pain.
At time 1 we have data on 37 subjects in the AB group and 45 in the BA group. Five of the
AB subjects and 10 of the BA subjects dropped out before the time 2 response was recorded.
The trial, in common with many crossover trials, required the subjects to receive treatment
over a fairly long time interval, in this case six weeks. Thus the subjects who dropped out
before the time 2 response are extremely likely to have had some experience of their second
treatment.
There are again no covariates other than treatment type and time. Without treatment by
time interaction the parameter vector is β = (µ, pi, τ) and the design matrices Xi are all
either
(
1 1 1
1 −1 −1
)
or
(
1 1 −1
1 −1 1
)
depending on whether the subject is given treatment in order AB or BA respectively.
Figure 3 shows the range of treatment effects obtained using the methods we have described.
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Figure 2: Longitudinal trial: means and sample sizes used for calculation. Panel (a): as
reported, using LOCF. Panel (b): observed data. Panel (c): completers and dropouts
separated at time 1.
It seems there are relatively little differences between estimates, which is not surprising as
the proportion of dropouts is low (15/92 or 16%). However, some of the differences are
marked and there is wide variation in estimated standard errors. The estimated treatment
effect under complete case for instance is τˆ = 2.85 (SE 1.19), which is little more than half
that obtained under the ZI procedure (τˆ = 4.862, SE 2.68).
4 Complete-Case Analyses
4.1 Relationship of CC estimators to MNAR estimators
If the distribution of Yi2(0) is not the same as that of Yi2(1), then an analysis that attempts
to compensate for the missing data, for example by assuming data are MNAR, is of no merit.
If the data were not missing, then in almost all circumstances they would be expected to have
a different distribution. In such instances the temporal strategy of Section 2.2, including
a CC analysis, should be preferred. Nevertheless, effect on the required inferences of this
choice is of practical importance, so an exploration of the properties of a CC analysis when
the data are MNAR is of interest.
One such property is the expectation of the estimators of the treatment effect, τˆLONG for
the longitudinal study, and τˆCO for the crossover design from a CC analysis. For the simple
two-period designs the estimators are
τˆLONG =
1
4
(S¯AA − S¯BB) τˆCO = 1
4
(D¯AB − D¯BA),
where S¯AA denotes the mean of the Si = Yi1 + Yi2 for complete cases in sequence AA, with
the other terms defined similarly and with Di = Yi1 − Yi2. These estimators are unbiassed
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Figure 3: Crossover trial: selection of estimated treatment effects and nominal 95% confi-
dence intervals
in the sample space of complete cases and we denote their expectations by τCCLONG and τ
CC
CO ,
respectively. These parameters will, in general, differ from the treatment effect τ introduced
in Section 3.1 that would apply if, e.g., a MNAR analysis were used when the distribution
of Yi2(Ri = 0) did coincide with that of Yi2(Ri = 1). Analytic approximations for the
relationship between these parameters can be derived if we are prepared to assume that the
distribution of (Y1, Y2)
T is bivariate Normal with density f(Y1, Y2).
The key quantities required are E(Yi1 + Yi2 | Ri = 1) for each of the sequences in the
longitudinal trial, and E(Yi1 − Yi2 | Ri = 1) for the sequences of the crossover design.
Omitting the subscript i, these can be evaluated as
E(Y2 ± Y1 | R = 1) =
∫ ∫
(Y1 ± Y2)expit(θ0 + θ1Y1 + θ2Y2)f(Y1, Y2)dY1dY2∫ ∫
expit(θ0 + θ1Y1 + θ2Y2)f(Y1, Y2)dY1dY2
.
If the unconditional mean of Yij in sequence rs is µrsj then the above can be written as
µrs1 ± µrs2 +
∫ ∫
(z1 ± z2)expit(Θrs + θ1z1 + θ2z2)φ2(z1, z2 | Ω)dz1dz2∫ ∫
expit(Θrs + θ1z1 + θ2z2)φ2(z1, z2 | Ω)dz1dz2 (9)
where Θrs = θ0 + θ1µrs1 + θ2µrs2 and (Z1, Z2)
T is a bivariate Normal variable with mean
zero, dispersion matrix Ω and density φ2(z1, z2 | Ω). We will assume that the variances in
Ω are both equal to σ2 and that the covariance is ρσ2. The integrals can be approximated
if we note that expit(u) ≈ Φ(cu) where Φ(·) is the standard Normal distribution function
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and c = (16
√
3)/(15pi)35. A convenient method of evaluation is to note that Φ(c[Θrs +
θ1z1 + θ2z2])φ2(z1, z2 | Ω) is proportional to the density of an extended skew-Normal (ESN)
distribution (see Appendix and36), and the normalising constant is the denominator of (9),
after the application of the approximation to expit(·).
Applying the formula for the expectation of the ESN we obtain
E (Z1 ± Z2) ≈ ck−10 eT±Ωθ12ζ(cΘrs/k0) =
cσ2
k0
(1± ρ)(θ1 ± θ2)ζ(cΘrs/k0)
where θ12 = (θ1, θ2)
T , k0 =
√
1 + c2σ2(θ21 + θ
2
2 + 2ρθ1θ2) and e
T
±
= (1, ±1). Also ζ(u) =
φ(u)/Φ(u), with φ(u) denoting the density of a standard Normal variable.
From these expressions we can approximate τCCLONG and τ
CC
CO , using the parametrisation in-
troduced in Section 3.1, when the data are MNAR with continuation probability expit(θ0 +
θ1Y1 + θ2Y2). For the longitudinal design we obtain
τCCLONG ≈ τ +
1
4
cσ2
k0
(1 + ρ)(θ1 + θ2)(ζ(
cΘAA
k0
)− ζ(cΘBB
k0
)), (10)
and for the crossover design
τCCCO ≈ τ +
1
4
cσ2
k0
(1− ρ)(θ1 − θ2)(ζ(cΘAB
k0
)− ζ(cΘBA
k0
)). (11)
For the longitudinal design ΘAA = Θ + τ(θ1 + θ2) and ΘBB = Θ − τ(θ1 + θ2), with Θ =
θ0 + µ(θ1 + θ2) + pi(θ1 − θ2), whereas for the crossover design we have ΘAB = Θ+ τ(θ1 − θ2)
and ΘBA = Θ− τ(θ1 − θ2). If the deviations of the Θrs from Θ are small then (10) and (11)
can be written as
τCCLONG ≈ τ
(
1 +
1
2
c2σ2
k20
(1 + ρ)(θ1 + θ2)
2ζ ′(
cΘ
k0
)
)
(12)
τCCCO ≈ τ
(
1 +
1
2
c2σ2
k20
(1− ρ)(θ1 − θ2)2ζ ′(cΘ
k0
)
)
(13)
Since ζ ′(u) = −ζ(u)(u+ ζ(u)) < 0 for all u, it follows that both τCCLONG and τCCCO are shrunk
versions of τ , i.e. they are closer to zero than τ . Consideration of (10) and (11) shows that
the biases operate in the same direction even when the deviations are not small.
If the treatment effect τ vanishes then it follows that Θrs = Θ and hence τ
CC
LONG and τ
CC
CO
also vanish. These expressions also reveal that CC analysis and the MNAR analysis coincide
if the data are MCAR (θ1 = θ2 = 0). They do not agree when the data are MAR but not
MCAR (θ2 = 0, θ1 6= 0). However, if data are MNAR they do agree in some special cases.
For the longitudinal design this occurs when θ1 = −θ2 and, for the crossover design, when
θ1 = θ2. Some insight into this circumstance can be found by rewriting (4) as
Pr(Ri = 1 | Yi1, Yi2) = expit(θ0 + 12(θ1 − θ2)Di + 12(θ1 + θ2)Si).
If θ1 = θ2 then the dropout probability depends on the data only through Si, that is the
chance of dropping out depends on the mean level of the response, whereas if θ1 = −θ2 then
the dropout probability depends only on the increments in response, Di. In the longitudinal
design the estimate of the treatment effect depends solely on the mean level of the response.
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If θ1 = −θ2, then the probability of dropping out of the study will depend only on the
increments in response, and our error model ensures that Si and Di are independent, so the
coincidence of τ and τCCLONG is unsurprising. By contrast in the crossover design, the MNAR
and the CC estimands coincide if the dropout probability depends only the Si. This result
is reminiscent of Little’s observation that in a pattern-mixture model intended to estimate
the mean difference between period 1 and period 2, a CC analysis is to be preferred if the
dropout probability depends on Si
37.
4.2 Meaning of parameters
When interpreting the relationships derived above it is important to remain clear about the
meanings of the parameters τ , τCCLONG and τ
CC
CO . In Section 3.1 it was stated that τ is the
parameter of interest. However, while this would be so for most standard analyses, a case
can be made that this is not always the correct target for our inference.
Consider a crossover design to compare two active treatments, in which some subjects are
unable to tolerate one or other of the treatments. In this case the response that would
have been observed had the subject tolerated the treatment is not meaningful. In these
circumstances a MNAR analysis is inappropriate. On the other hand a CC analysis might
be justified on the grounds that it compares subjects who can tolerate both treatments. The
validity of this analysis stems from the fact that it is precisely for these subjects that the
trial comparison is relevant. The decision to specialise the analysis to this subgroup means
that the appropriate target for inference is τCCCO .
Even in circumstances where it makes sense to identify Yt(1) and Yt(0), a MNAR approach
may not be the right analysis. Consider for instance an analgesic trial in which all subjects
can tolerate both treatments, but some drop out because of a side-effect which makes the
treatment impractical. For example, subjects on a particular treatment may not be allowed
to drive and hence some may refuse the treatment. While one can now sensibly believe
that both potential outcomes have the same distribution, the side-effect means that both
treatments are a practical proposition only for a subset of subjects and the most pertinent
analysis is provided by the complete cases. In this case it is doubtful if the dropout model (4)
with the outcomes as the only covariates would adequately describe the missingness process.
It could be argued that it is unfair to dismiss a MNAR analysis if the dropout model is
mis-specified but, nevertheless, in such an example a CC analysis has the advantages that it
is practical, germane and has a readily described rationale.
5 Discussion
In Section 4.2 we argued that that there are circumstances where the complete case parame-
ters τCCCO or τ
CC
LONG are the natural parameters of interest. In other situations the underlying
parameter τ may indeed be the original target for inference but if the data are blighted by
significant dropout it may be unreasonable to attempt to estimate this inestimable param-
eter given the data to hand. In these circumstances case a CC analysis may be the only
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practical alternative, but if τ really is the appropriate target for inference, is this adequate?
If the overall level of missingness is low then a CC analysis is unlikely to differ substantially
from more sophisticated analyses. Indeed, analyses that link the estimation of treatment
parameters to parameters describing dropout may be compromised if there is limited infor-
mation on the dropout process. On the other hand, as the proportion of the patients in the
trial who are retained in a CC falls, the CC analysis will provide useful information about a
smaller and rather different population from that originally envisaged. However, as we have
argued, this subset of patients may be of particular relevance. In these circumstances a sup-
plementary analysis that seeks to determine the factors affecting dropout becomes necessary.
Consider the longitudinal data of Section 3.1. If the sole focus is on τ then Figure 1 shows
that we can choose any or none of a range of estimates. But Figure 2 summarises the true
picture and we suggest that an appropriate analysis should proceed as described in Section
2.2. First we analyse Y1 only and find and report a strong treatment effect to this time of
0.55 units with standard error 0.09. Such an analysis is sensible for these data because the
time 1 measurement is not baseline as the subjects had already received treatment before the
measurement was obtained. Second we model dropout as a logistic model in either Y1 only
or, with the remarks of Section 4.2 in mind, in Y1 and treatment (or other covariates). Omit-
ting details, it turns out that for these data there are strong effects on dropout of both Y1
and treatment group. These should be discussed with the experimenter. Finally, we perform
a complete case analysis and state that for subjects who continue to the second time point
there is no evidence of difference between treatment groups in mean response levels at either
time point. The conclusions are more complex than initially desired but then so are the data.
A CC analysis of a randomized trials will suffer from the complication that the groups of
complete cases will not exhibit the balance conferred by the initial randomization. The
effect of this on inferences will need to be considered carefully if a CC analysis is being
considered as the primary analysis. In our examples this issue may be less of a concern in
the CO study, as here each patient is essentially used as their own control. An imbalance
between the sequences could masquerade as a treatment by period interaction but, if the
investigator is confident that the design has excluded carryover effects, such interactions are
likely to represent differences in overall level of response, and the Di will be unaffected. The
problem of loss of balance in randomized groups is likely to pose a greater challenge for the
parallel-group design.
An abiding concern of investigators is the loss of efficiency that results from missing data.
This problem may seem to be exacerbated if a CC analysis is used, as data from partially
observed cases is ignored. However, the relative efficiencies of alternative analyses should
only be a concern if both approaches estimate the same quantity. If data are MNAR then
methods such as those exemplified in Section 2 will not, in general, estimate the same quan-
tity. Consequently, the relative performance of these methods cannot be assessed through
simple comparisons of standard errors.
While there may be arguments in favour of CC analyses, there could be circumstances where
what constitutes a CC analysis is unclear. In our examples matters are straightforward but
consider a crossover trial comparing three treatments over three periods. Suppose that it
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is required to estimate the contrast between two of the treatments. Does a CC analysis
retain only patients providing three observations, or should we use all patients who provide
information on the two treatments being compared? The issue becomes even murkier if we
consider long sequences of irregularly timed measurements, especially common in observa-
tional data rather than designed trials.
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Appendix: Properties of the extended skew-Normal dis-
tribution
A p-dimensional random variable U has an extended skew-Normal distribution, ESN(ξ,Σ, α, ν),
if it has density
φp(u; ξ,Σ)Φ(α
T (u− ξ) + ν)
Φ(ν¯)
, (14)
where the parameters ξ and α are p-dimensional vectors, ν is a scalar, Σ is a p×p dispersion
matrix and ν¯ = ν(1 + αTΣα)−
1
2 . Here Φ(.) is the CDF of a univariate standard Normal
variable and φp(.; ξ,Σ) is the density of a p-dimensional Normal variable with mean ξ and
dispersion Σ. It follows that
E(U) = ξ +
Σα√
1 + αTΣα
φ(ν¯)
Φ(ν¯)
,
and φ(.) is the density of a univariate standard Normal variable.
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